Kids Develop Different Antibodies When They Get COVID-19
Get update on your WhatsApp
15 Nov 2020
One of the striking things about COVID-19 is that childrenTrusted Source who have contracted the new coronavirus rarely develop the kinds of severe respiratory and other symptoms seen in adults.
In addition, most children who develop COVID-19 have mild or no symptoms.
This doesn’t mean children are immune to the new coronavirus.
A small number of children with COVID-19 can develop a serious condition called multisystem inflammatory syndrome in children (MIS-C)Trusted Source. Scientists aren’t certain, though, why some children get very sick and others don’t.
A new studyTrusted Source published Nov. 5 in the journal Nature Immunology adds to our understanding of the differences between how children and adults respond to SARS-CoV-2.
Researchers from Columbia University and other institutions found that children’s immune response to SARS-CoV-2 is distinct from that of adults. This was true even in children who developed MISC-C.
Shane Crotty, PhD, a virologist at the La Jolla Institute for Immunology, said this finding wasn’t a given.
“Children definitely have a different disease outcome from adults,” he said, “but that could be for a lot of different reasons.”
Distinct immune response in children with COVID-19
After analyzing blood samples taken from adults and children, researchers saw that children who had contracted the new coronavirus produced lower levels of neutralizing antibodies and fewer types of antibodies.
The immune system can produce many different antibodies specific to a virus. Neutralizing antibodiesTrusted Source bind in a way that blocks infection.
The results of the study don’t mean that children’s immune response was weaker, because that implies that “more is better,” said Dr. Ravi Jhaveri, associate division head of infectious disease and professor of pediatrics (infectious diseases) at the Ann & Robert H. Lurie Children’s Hospital of Chicago.
“The adult patients with the worst symptoms of ARDS [acute respiratory distress syndrome] had the highest levels of antibody,” Jhaveri said, “while children with varying levels of symptoms, mostly milder, had lower responses.”
Even among adults, those with severe symptoms had higher levels of neutralizing antibodies compared to adults with mild symptoms.
Again, the higher levels of neutralizing antibodies didn’t correlate with better disease outcomes.
“People tend to oversimplify that neutralization is all we should care about, but this may not be the whole story,” Jhaveri said. “Sometimes the best antibodies are the ones that help the immune cells find and destroy a virus.”
Researchers didn’t look at this kind of immune activity.
Sean Diehl, PhD, an associate professor of microbiology and molecular genetics at the University of Vermont, said another interesting finding of the study is that the adults produced antibodies that bound to more parts of the virus.
“Adults are targeting both the outer spike protein, as well as the nucleocapsid that binds to and protects the genome of the virus,” he said. “But kids are only making antibodies against the spike protein.”
This could have implications for coronavirus testing. Some antibody tests, including those made by Abbott and RocheTrusted Source, look only for antibodies that bind to the nucleocapsid. These tests may miss children who currently have the new coronavirus or who had an infection in the past.
Diehl said adults may be producing more types of antibodies because they have a higher viral load than children. The researchers didn’t measure how much virus people had in their body, so this connection isn’t clear.
However, the fact that both children and adults produced neutralizing antibodies against the spike protein bodes well for COVID-19 vaccines, Diehl said.
Many vaccine candidates currently being studied target the spike protein. Preliminary data from some phase 3 trials suggest that these vaccines are effective in adults. This suggests they may also work in children, who haven’t been included in many of the ongoing trials.
In the new study, researchers analyzed antibodies from a single point in time from 79 participants in four groups:
convalescent plasma donors who had recovered from COVID-19 without being hospitalized
adults hospitalized with severe COVID-19 ARDS
children hospitalized with MIS-C
children who had a coronavirus infection but didn’t develop severe illness
The study was too small to show whether children’s antibody levels differed with age. The blood samples also came from one hospital in one region of the country, so the results may not apply to everyone.
Source : healthline feeds
It will be great, if you share your view on above write-up.
Your content has been submitted
An error occurred. Try again later